(4S,5S)-4-isobutyl-5-vinyloxazolidin-2-one | 109864-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4S,5S)-4-isobutyl-5-vinyloxazolidin-2-one
• 英文别名: (4S,5S)-4-isobutyl-5-vinyl-2-oxazolidinone；(4S,5S)-4-(2-methylpropyl)-5-vinyloxazolidin-2-one；4(S)-isobutyl-5(S)-vinyl-2-oxazolidinone；(4S,5S)-4-isobutyl-5-vinyl-2-oxazolidone；(4S,5S)-5-ethenyl-4-(2-methylpropyl)-1,3-oxazolidin-2-one
• CAS: 109864-64-4
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: HWPXKZRGHXLELE-YUMQZZPRSA-N

物化性质

• 沸点：
  312.3±22.0 °C(Predicted)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4S,5S)-4-isobutyl-5-vinyloxazolidin-2-one 在 sodium hydroxide 、 9-borabicyclo[3.3.1]nonane dimer 、 双氧水 作用下， 生成 (4S,5S)-4-异丁基-5-(2-羟乙基)恶唑烷-2-酮
  参考文献：
  名称：

  通过氨基甲酸叔丁基二甲基硅烷基酯形成环状氨基甲酸酯的新模式。他汀类药物及其类似物的立体选择性合成

  摘要：

  使用S N 2'（由AgF或AgF-Pd（II）引发）由叔丁基二甲基甲硅烷基氨基甲酸酯形成的环状氨基甲酸酯，进行1,2-和1,3-氨基羟基系统的立体选择性构建。该方法有效地应用于了他汀类药物和AHPPA的合成。

  DOI：

  10.1016/s0040-4039(00)96439-6
• 作为产物：
  描述：

  N-叔丁氧羰基-L-亮氨醇 在 2,6-二甲基吡啶 、 N-氯代丁二酰亚胺 、 pyridine-SO3 complex 、 三氟化硼乙醚 、 silver fluoride 、 二异丁基氢化铝 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 (4S,5S)-4-isobutyl-5-vinyloxazolidin-2-one
  参考文献：
  名称：

  通过氨基甲酸叔丁基二甲基硅烷基酯形成环状氨基甲酸酯的新模式。他汀类药物及其类似物的立体选择性合成

  摘要：

  使用S N 2'（由AgF或AgF-Pd（II）引发）由叔丁基二甲基甲硅烷基氨基甲酸酯形成的环状氨基甲酸酯，进行1,2-和1,3-氨基羟基系统的立体选择性构建。该方法有效地应用于了他汀类药物和AHPPA的合成。

  DOI：

  10.1016/s0040-4039(00)96439-6

文献信息

• Angiotensinogen analogs
  申请人：Abbott Laboratories

  公开号：US04857507A1

  公开（公告）日：1989-08-15

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen, R.sub.3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R.sub.5 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.2 and R.sub.4 are independently selected from hydrogen and loweralkyl; R.sub.6 is CHOH or CO; R.sub.7 is CH.sub.2, CF.sub.2 or CF with the proviso that when R.sub.6 is CO, R.sub.7 is CF.sub.2 ; R.sub.8 is CH.sub.2, CHR.sub.14 wherein R.sub.14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R.sub.7 and R.sub.8 taken together can be ##STR3## with the proviso that when R.sub.7 is CF.sub.2, R.sub.8 is CH.sub.2 ; E is O, S, SO, SO.sub.2, NR.sub.15 wherein R.sub.15 is hydrogen or loweralkyl or NR.sub.16 CO wherein R.sub.16 is hydrogen or loweralkyl; R.sub.9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R.sub.9 taken together can be N.sub.3, with the proviso that when E is NH, R.sub.9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。
• Stereoselective vinylation of amino aldehydes using 2-trimethylsilylethylidentriphenylphosphorane
  作者：Maurizio Franciotti、André Mann、Maurizio Taddei

  DOI：10.1016/s0040-4039(00)93602-5

  日期：1991.11

  2-Trimethylsilylethylidentriphenylphosphorane reacts stereoselectively with α-amino aldehydes giving the Cram chelation controlled product of vinylation of the carbonyl group. The olefinic 1,2-amino alcohols obtained with this reaction are important intermediates for the preparation of peptides analogues and they were employed for the preparation of N-Boc-statine.

  2-三甲基甲硅烷基乙基三苯苯基膦烷与α-氨基醛立体选择性地反应，得到羰基乙烯基化的Cram螯合控制产物。通过该反应获得的烯属1,2-氨基醇是制备肽类似物的重要中间体，并且被用于制备N-Boc-他汀。
• Lipase-catalyzed Transesterification of Methyl 2-Substituted 3-Hydroxy-4-pentenoates and its Synthetic Application to the Taxol Side Chain
  作者：Tadakatsu Mandai、Tetsuta Oshitari、Masafumi Susowake

  DOI：10.1055/s-2002-34247

  日期：——

  Syn-and anti-methyl 2-substituted 3-hydroxy-4-pentenoates were efficiently resolved in lipase-catalyzed transesterification. This protocol was successfully applied to the synthesis of the taxol side chain.

  辛基和反式甲基2取代的3-羟基-4-戊烯酸酯在脂酶催化的转酯化反应中高效分离。该方法成功应用于紫杉醇侧链的合成。
• Retroviral protease inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0342541A2

  公开（公告）日：1989-11-23

  A retroviral protease inhibiting compound of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof.

  一种抑制逆转录病毒蛋白酶的式化合物： 或其药学上可接受的盐、原药或酯。
• <i>N</i>-Boc Amines to Oxazolidinones via Pd(II)/Bis-sulfoxide/Brønsted Acid Co-Catalyzed Allylic C–H Oxidation
  作者：Thomas J. Osberger、M. Christina White

  DOI：10.1021/ja506036q

  日期：2014.8.6

  A Pd(II)/bis-sulfoxide/Bronsted acid catalyzed allylic C-H oxidation reaction for the synthesis of oxazolidinones from simple N-Boc amines is reported. A range of oxazolidinones are furnished in good yields (avg 63%) and excellent diastereoselectivities (avg 15:1) to furnish products regioisomeric from those previously obtained using allylic C-H amination reactions. Mechanistic studies suggest the role of the phosphoric acid is to furnish a Pd(II)bis-sulfoxide phosphate catalyst that promotes allylic C-H cleavage and pi-allylPd functionalization with a weak, aprotic oxygen nucleophile and to assist in catalyst regeneration.